(PFE)

Shares of Pfizer ( NYSE: PFE ) have been battered over the past month, falling by -16.44%, outpacing the market's loss of -9.44% over the same period.

2025 hasn't been kind to investors amid rising concerns about a recession and tariffs.

The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.

Despite its historical underperformance and declining dividend growth trajectory, Pfizer's 7.63% dividend yield is attractive, making it a compelling income stock candidate. CEO Bourla's strategic foc...

Every cloud has a silver lining. Sometimes, they have two.

It's been a tough start to 2025 for investors amid concerns regarding the strength of the U.S. economy and uncertainties over the effect of sweeping changes in trade policy under the Trump administrat...

The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) has a reputation for being the go-to choice for income-focused investors who want both quality and yield.

Although it isn't the largest therapeutic area in the pharmaceutical industry, the market for weight loss therapies has caught fire in recent years. The leading medicines in this field include househo...

The past few weeks have been tough for the market. Tariffs are obviously a direct threat to most companies' top and bottom lines, while the broad economic weakness they might cause is nearly impossibl...

Pfizer (PFE) closed the most recent trading day at $22.15, moving +0.48% from the previous trading session.